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Abstract
Background: Early presentation for HIV care is vital as an initial tread in the UNAIDS 90–90–90 targets. However,
late presentation for HIV care (LP) challenges achieving the targets. This study assessed the prevalence, trends,
outcomes and risk factorsfor LP.
Methods: A 12 year retrospective cohort study was conducted using electronic medical records extracted from
an antiretroviral therapy (ART) clinic at Jimma University Teaching Hospital. LP for children refers to moderate or
severe immune-suppression, or WHO clinical stage 3 or 4 at the time of first presentation to the ART clinics. LP
for adults refers to CD4 lymphocyte count of < 200 cells/ μl and < 350 cells/μl irrespective of clinical staging, or
WHO clinical stage 3 or 4 irrespective of CD4 count at the time of first presentation to the ART clinics. Binary
logistic regression was used to identify factors that were associated with LP, and missing data were handled
using multiple imputations.
Results: Three hundred ninety-nine children and 4900 adults were enrolled in ART care between 2003 and 15.
The prevalence of LP was 57% in children and 66.7% in adults with an overall prevalence of 65.5%, and the 10-
year analysis of LP showed upward trends. 57% of dead children, 32% of discontinued children, and 97% of
children with immunological failure were late presenters for HIV care. Similarly, 65% of dead adults, 65% of
discontinued adults, and 79% of adults with immunological failure presented late for the care. Age between 25-
< 50 years (AOR = 0.4,95% CI:0.3–0.6) and 50+ years (AOR = 0.4,95% CI:0.2–0.6), being female (AOR = 1.2, 95% CI: 1.
03–1.5), having Tb/HIV co-infection (AOR = 1.6, 95% CI: 1.09–2.1), having no previous history of HIV testing (AOR =
1.2, 95% CI: 1.1–1.4), and HIV care enrollment period in 2012 and after (AOR = 0.8, 95% CI: 0.7–0.9) were the
factors associated with LP for Adults. For children, none of the factors were associated with LP.
Conclusions: The prevalence of LP was high in both adults and children. The majority of both children and
adults who presented late for HIV care had died and developed immunological failure. Effective programs should
be designed and implemented to tackle the gap in timely HIV care engagement.
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Background
The Joint United Nations Program on HIV and AIDS
(UNAIDS) has developed a 90–90–90 treatment tar-
get framework in order to end AIDS globally which
aims at 90% of people living with HIV knowing their
HIV status, 90% of HIV diagnosed patients receiving
sustained treatment, and 90% of those on HIV treat-
ment achieving viral suppression [1]. While diagnos-
ing HIV infection is vital as the initial tread in the
90–9090 targets, diagnosis per se is no longer suffi-
cient [2]. Early diagnosis and access to treatment
helps people with HIV to timely get and appropriately
use HIV treatment [3] that further reduces the virus
load and risk of morbidity and mortality. Neverthe-
less, late presentation for HIV care (LP) has been rec-
ognized as an impediment to meet the above
mentioned UNAIDS targets.
LP is the result of being late in HIV diagnosis and/or
late in linking with or in accessing HIV care [4]. The def-
inition of LP is disparate and is contextualized using the
threshold for ART eligibility [5]. To date, numerous defi-
nitions have been used including: i) when the baseline
CD4 count is < 200 or < 350 cells/μl and/or with an
AIDS defining disease [3, 6, 7], ii) when AIDS defining
conditions are diagnosed either before or during the
period to an HIV diagnosis [8], iii) when AIDS defining
conditions are diagnosed in the subsequent 6 months
period to an HIV diagnosis [9], or iv) when AIDS defin-
ing conditions are diagnosed 12 months period to an
HIV diagnosis [10].
LP is associated with increased risk of HIV transmis-
sion [11], ART drug resistance [11], and health care ex-
penses [12]. Additionally, LP has been acknowledged as
a challenge for the achievement of the ambitious
UNAIDS 90–90-90 targets [13, 14]. For the first 90, high
magnitude of late HIV diagnosis reflects that there are a
number of people who did not know their HIV status.
For the second 90, LP results in poor health outcomes
and this interrupts the sustainable uptake of the treat-
ment [13]. Furthermore, LP significantly contributes for
pre-ART deaths and, this in turn, reduces the number of
HIV diagnosed patients on ART [15]. For example, a
study from South Africa reported that ART initiation at
the time of first presentation to ART clinic boosted
treatment uptake by 36% [16]. For the third 90, LP
lowers the number of CD4 cells and increases the num-
ber of viral counts, and this causes clinical, immuno-
logical or virological failure [14, 17]. Previous studies
have shown that late diagnosis appeared to be the main
reason for virological failure, and ART initiation at first
visit increased viral suppression by 26% [16].
LP has been reported to be a significant problem
across the globe. In Europe, overall prevalence of 15–
66% has been reported [18, 19]. The magnitude of LP
in Asia was very significant (72–83.3%) [20], and in
Africa, the overall prevalence has been reported to be
between 35 and 65% [21, 22]. Nonetheless, heterogen-
eity in its measurement limited direct comparisons
[23]. In Ethiopia in 2015, there were 39,140 new
infections, 768, 040 people living with HIV and 28,
650 HIV/ADS deaths [24]. Universal access to ART
in the country was launched in 2005 [25], and to
date, the coverage of ART—the percentage of people
on ART among those in need of treatment [26]— is
52% [24]. However, the status of timely presentation
for HIV care is yet to be assessed. One cross-
sectional study from northern part of the country has
reported a LP prevalence of 68.8% [27].
Demographic, behavioural and clinical factors contrib-
uted for LP [6, 20, 28, 29]. For instance, being female,
older age, rural dwellers, alcohol users, ‘Khat’ chewers,
cigarette smokers, being diagnosed with sever co-
morbidities, perceiving HIV related stigma, having con-
tact with commercial sex workers and being exposed to
risky sexual behavior were the factors associated with LP
[6, 20, 28, 29]. In Ethiopia, other studies have assessed
factors affecting LP [6, 27, 29], and all except one were
from the northern part of the country.
However, it is well known that the southwestern part
of the nation has different cultural and socioeconomic
characteristics. It also has the highest HIV prevalence
(6.5%) in the country [30] and may have different LP
factors which need to be understood to address HIV in
these settings. In addition, for patients who started
ART, no study has been conducted to assess the out-
come and trends of LP. The prevalence of LP among
children has also not been determined. Given the above
gaps, and the clinical and public health importance of
early HIV diagnosis on timely ART commencement, it
is imperative to comprehend the LP situation and rec-
ommend effective programs that facilitate early presen-
tation for HIV care in Ethiopia. Furthermore,
addressing LP may have a substantial contribution for
SDG-3 to have good health and wellbeing, and particu-
larly for SDG-3.3 to end HIV epidemics by 2030. This
paper examines the prevalence, trend, outcomes and
risk factors of LP among children and adults enrolled
for ART in Jimma University Teaching Hospital
(JUTH), Southwest Ethiopia.
Methods
Study design, setting and participants
A retrospective cohort study was undertaken using data
extracted from the ART clinic at JUTH using patient
records from June 2003 to March 2015. Details of the
study setting has been described elsewhere [31]. The
study population was all HIV patients enrolled for ART
care in JUTH.
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Data source and procedures
The data were extracted from JUTH electronic medical
records (EMR) system called comprehensive care center
patient application database (C-PAD) that was in place
since 2007. HIV care providers record patient clinical
and non-clinical information on paper form, which is
then entered into the EMR by data clerks. Two data
clerks perform the data entry process to ensure com-
pleteness. The International Center for AIDS Care and
Support (ICAP) at Colombia University was also deliver-
ing technical assistance on the electronic patient level
data management, and has been conducting random
check up of data completeness. This ensures the accur-
acy and reliability of the EMR data. Weekly patient sum-
mary generated from the EMR system helps to flag
patients with conditions that seek follow-up. If baseline
CD4 and WHO clinical staging were not recorded,
records would be excluded.
Study variables and definitions
The dependent variable was the time when a patient
presented for HIV care and was dichotomized as late or
early. We defined LP for adults when the baseline CD4
cells count is < 200 cells/μl or < 350 cells/μl (pre-and
post-revision of national ART guideline) irrespective of
WHO clinical staging, or WHO clinical stage 3 or 4 irre-
spective of CD4 count at the time of first presentation to
an ART clinic [3, 6]. Early presentation for HIV care
(EP) is the opposite of LP. LP and EP for children are
defined in Table 1. The independent variables included
age, sex, marital status, educational status, religion, Tb/
HIV co-infection, baseline functional status, history of
HIV testing, and HIV care enrollment period. History of
previous HIV testing refers to testing (one or more
times) for HIV before diagnosis. HIV care enrollment
period was dichotomized as enrolled for HIV care in
2003–11, and 2012 and after.
Possible outcomes of LP were ART discontinuation,
immunological failure and mortality. ART discontinu-
ation is attributed to lost to follow up (LTFU), defaulting
and stopping medication while remaining in care. LTFU
was if patients had been on ART treatment and had
missed at least three clinical appointments but had not
yet been classified as “dead” or “transferred out” (TO).
Defaulting was if patients had been on ART treatment
and had missed less than three clinical appointments
but had not yet been classified as “dead” or “TO”. Stop-
ping medication was definedwhen patients had stopped
treatment due to any reason while they have remained
in care. TO is the official transferring of the patient to
another ART clinic within or outside a catchment area.
Immunological failure was defined based on the defini-
tions provided by WHO [32]. Mortality (all cause mor-
tality) is the death of people on ART in the reporting
period. Table 1 reports the measurements of LP.
Statistical analyses
Ten year trends (data for years 2003 and 2015 were
excluded since their number of months were incomplete)
for LP was described by line graphs, and best-fit equation
for the trend line was developed. We described the per-
centage of LP by ART discontinuation, immunological
Table 1 Measurements for late presentation for HIV care (LP)
Adults Late presentation for HIV care [6, 35]a
Enrolled in 2003–11 Enrolled in 2012–15
CD4 lymphocyte count of < 200 cells/ μl irrespective
of WHO clinical stage at the time of first presentation
to the HIV care
CD4 lymphocyte count of < 350 cells/ μl irrespective of WHO clinical stage at the
time of first presentation to the HIV care
WHO clinical stage 3 or 4 irrespective of CD4 count
at the time of first presentation to the HIV care b
WHO clinical stage 3 or 4 irrespective of CD4 count at the time of first presentation
to the HIV care
Childrenc Late presentation for HIV care [70]
Moderate immune-suppression (damage)
if CD4 count between
Severe immune-suppression (damage)
if CD4 count between
0–12 months 750–1500 cells/ μl < 750 cells/ μl
1–5 years 500–1000 cells/ μl < 500 cells/ μl
≥ 6 years 200–500 cells/ μl (enrolled in 2003–2011) < 200 cells/ μl (enrolled in 2003–11)
≥ 6 years 350–500 cells/ μl (enrolled in 2012–2015) < 350 cells/ μl (enrolled in 2012–2015)
ART: antiretroviral therapy; CD4: cluster for differentiation 4; WHO: World Health Organization; Tb: Tuberculosis; PCP: pneumocystis carinii (juvenii) pneumonia
aThe definition for LP among Tb/HIV co-infected population was only based on the CD4 criteria [4]
bWHO clinical Stage 3was defined if one of the following is present in an HIV diagnosed patient: weight loss of > 10% body weight, chronic diarrhea for >
1 month, fever for > 1 month, oral candidiasis, oral hairy leukoplakia, or pulmonary Tb within the previous year, or severe bacterial infections; WHO clinical Stage 4
was defined if one of the following is present in an HIV diagnosed patient: HIV wasting syndrome, PCP, toxoplasmosis of the brain, cryptosporidiosis or
isosporiasis with diarrhea for > 1 month, cytomegalovirus disease of an organ other than liver, spleen or lymph node, herpes simplex virus infection, progressive
multifocal leukoencephalopathy, candidiasis, extra-pulmonary Tb, lymphoma, kaposi’s sarcoma, HIV encephalopathy
cLP is also defined if WHO clinical stage 3 or 4 at first visit to the ART clinics
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failure and mortality to show the outcomes of LP. The dif-
ferences between LP and its outcomes were checked using
Chi square tests. We used binary logistic regression to
identify factors that were associated with LP. Multi-
collinearity was checked using variance inflation factor
and none was found. In addition, we checked for potential
two-way interactions and none was found.
Missing data was treated using multiple imputations
(n = 5) assuming missing at random (MAR) pattern [33]
and the model was reported with pooled imputed
values [34]. We developed an imputation model for
adults, however; for children, we did not decide to do
the multiple imputations analysis since the missing
values for the great majority of the variables were not
significant (below 5%). Bivariate logistic regression
analysis was conducted to determine the presence of
crude association and nominate the candidate variables
(P < 0.25 was considered) to multiple logistic regression.
P-value ≤ 0.05 was considered as a cutoff value for stat-
istical significance in the final multiple logistic regres-
sion model. We applied Hosmer and Lemeshow test to
check goodness of fit of the final model and was found
fit (P–value = 0.17). We reported odds ratio and 95%
confidence interval to summarize the data. We used
Statistical Package for the Social Sciences (SPSS)
version 22.0 for all data analyses.
Results
Of the 8172 patients enrolled for HIV care between 21
June 2003 and 15 March 2015, 5299 (64.8%) patients on
ART, the study population for the study, were included.
Of the total patients enrolled for ART, 4900 (92.5%)
were adults and 399 (7.5%) were children.
Table 2 demonstrates the characteristics of HIV
patients on ART. Among the children, 58.1% were
aged 5–15 years, 52.4% were males, and 73.9% were
Christians. The majority of the children (79.4%) had
moderate or severe immune-suppression, and half of
the children had baseline WHO clinical stage 3 or 4.
A total of 114 (28.6%) children had Tb/HIV co-
infection. The median time on ART and estimated
survival time, respectively, was 40 and 104.2 (99.8–
108.5) months. Among adults, three fifth (59.8%) were
females, about half (48.7%) were married and 39%
had primary school education. Two fifth (41.6%) of
adults had no history of HIV testing. A significant
number of adults (73.6%) had baseline CD4 count
below 200 cells/mm3, and 54.3% had WHO clinical
stage 3 or 4. Over a quarter of adults (27.9%) had
Tb/HIV co-infection. Twenty nine (0.9%) adults chan-
ged ART regimen during the course of the period.
The median time on ART was 49 months, and the
median estimated survival time was 121.9 (95%CI:
120.3–123.5) months.
Prevalence, trend and outcomes of LP
The overall prevalence of LP was 65.5%, and females
accounted for the majority (64.3%).In total, 215 children
(57%) and 1788 adults (66.7%) were late presenters. In
the period between 2004 and 2014 the percentage of LP
decreased from 83% to 62%. Fig. 1 shows the trend in
LP among HIV infected people on ART.
Table 3 reports the outcomes of LP among HIV in-
fected children and adults enrolled in HIV care. Of the
children, 57.1% of those who died, 32.3% of those who
discontinued care, and 96.9% of those who had immuno-
logic failure were late presenters for HIV care. Of adults,
64.7% of those who died, 65.3% of those who discontin-
ued care, and 78.7% of those who had immunologic fail-
ure presented late for the HIV care. The chi-square
analysis showed that the difference between LP and, im-
munologic failure and discontinuation for children was
statistically significant. For adults, LP was not statisti-
cally different with mortality and ART discontinuation.
Risk factors for LP
Table 4 presents the multiple logistic regression analysis
of factors for LP obtained from the complete case
analyses. Predictors of LP among adults included being
older adult, female, having Tb/HIV co-infection, having
no previous history of HIV testing and HIV care enroll-
ment period in 2012 and after. Older adults aged between
25- < 50 years (AOR = 0.4, 95% CI: 0.3–0.6) and 50+ years
(AOR = 0.4, 95% CI: 0.2–0.6) were 60% each less likely to
present late for HIV care compared to those aged between
15 and 25 years. Females were 20% high likely (AOR = 1.2,
95% CI: 1.03–1.5) to present late for HIV care than their
comparator. HIV patients with Tb/HIV co-infection were
about 2 times at risk of LP (AOR = 1.6, 95% CI: 1.09–2.1)
than HIV patients alone. In addition, while having no pre-
vious history of HIV testing (AOR = 1.2, 95%CI: 1.1–1.4)
was a risk factor for LP, HIV care enrollment period in
2012 and after (AOR = 0.8, 95% CI: 0.7–0.9) was a protect-
ive factor for LP. No statistically significant predictor was
found for LP among children.
Multiple imputations (MI)
To handle the missing data, we applied MI using five
imputed data sets. We have presented the results from
MI and complete case analyses in Table 4. In estimating
factors associated with LP among adults, results were
similar in both MI and complete case analyses except
for variables Tb/HIV co-infection and previous history
of HIV testing were marginally statistically significant in
the MI analysis.
Discussion
LP has been described as a sizable obstacle to attaining
the UNAIDS 90–90-90 and 95–95-95 targets [7, 14].
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Table 2 Clinical & non-clinical characteristics of HIV infected people enrolled in ART care in Southwest Ethiopia from 2003 to 2015
Variable Children (N = 399) Adult (N = 4900)
N (%) N (%)
Age in years < 1 21 (5.3) –
1- < 5 146 (36.6) –
5- < 15 232 (58.1) –
15- < 25 – 711 (14.5)
25- < 50 – 3937 (80.3)
50+ – 252 (5.2)
Median (range) age in years 6 (< 1–14) 30 (15–81)
ART follow up time in months,
median (range)
40 (0–116) 49 (0–137)
Estimated survival time in months,
median (95%CI)
104.2 (99.8–108.5) 121.9 (120.3–123.5)
Sex Male 209 (52.4) 1971 (40.2)
Female 190 (47.6) 2929 (59.8)
Marital status Never married – 897 (18.3)
Married – 2094 (42.7)
Separated/divorced/widowed – 1311 (26.8)
Missing – 598 (12.2)
Education No education – 945 (19.3)
Primary – 1687 (34.4)
Secondary and above – 1685 (34.4)
Missing – 583 (11.9)
Religion Muslim 47 (11.8) 1402 (28.6)
Christianb 133 (33.3) 2893 (59)
Missing 219 (54.9) 605 (12.3)
Baseline WHO classification 1 or 2 108 (27.1) 1355 (27.7)
3 or 4 110 (27.6) 1608 (32.8)
Missing 181 (45.3) 1937 (39.5)
Baseline CD4 count category No damage 72 (20.6) –
Moderate or severe damage 277 (79.4) –
Median (range) CD4 count 282 (0–2250) –
Baseline CD4 count (cells/mm3) < 200 156 (39.1) 3275 (66.8)
≥ 200 193 (48.4) 1174 (24)
Missing 50 (12.5) 451 (9.2)
Median (range) 282 (0–2250) 156 (0–1313)
History of Tb/HIV co-infection No 285 (71.4) 3533 (72.1)
Yes 114 (28.6) 1367 (27.9)
ARV adherence Good 319 (79.9) 4064 (82.9)
Fair or poor 80 (20.1) 836 (17.1)
Cotrimoxazole adherence Good 315 (78.9) 4119 (84)
Fair or poor 84 (21.1) 762 (15.6)
Missing – 19 (0.4)
History of HIV testing Yes 399 (100) 2860 (58.4)
No 0 (0) 2040 (41.6)
ART shift No 214 (97.7) 3190 (65.1)
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This study has shed light on the general problems of late
HIV care—magnitude, trend, outcomes and its risk fac-
tors. In the current study, the overall prevalence of LP
was considerably high (65.5%). Furthermore, the trends
of LP had shown persistently elevated prevalence (be-
tween 54% and 83%) although a lessening pattern was
observed. This finding is consistent with another finding
conducted in the country [27]. The prevalence of LP in
the current study (65.5%) was lower (72–83.3%) than the
prevalence from studies conducted in Asia [20], but
higher than the findings from other studies in Africa
that reported between 35 and 65% [21, 22]. This implies
that LP in Ethiopia is still highly prevalent even after the
introduction of universal ART.
The high and persistent LP prevalence may be due to:
i) lack of information [35], ii) persistently high level of
HIV related stigma [3, 27], iii) low HIV risk perception
[27, 35] especially among high risk groups [36], iv) use
of traditional treatment [27], v) poor integration between
modern medicine and traditional healers, and vi) phas-
ing out of international funding agencies [37].
Additionally, it could also be attributed to poor access to
HIV services [37, 38]. For example, only 79% of the total
health facilities in Ethiopia deliver HIV counseling and
testing services [39]. Primary Health Care principles and
scholars describe characteristics of accessible health sys-
tems to be approachable, acceptable, available, affordable
and appropriate for the target population [40, 41], and
thus raising a question whether HIV services are access-
ible to all HIV patients in Ethiopia. As such, LP issues
should be given top priority if Ethiopia is to meet the
UNAIDS targets.
Several strategies including the use of technology have
been recommended to reduce LP prevalence in develop-
ing countries. For example, in collaboration with
UNICEF, Amukele and colleagues successfully piloted
unmanned aerial systems (drones) for transporting
laboratory specimens to reduce late infant diagnosis in
Malawi [42]. Other programs such as using mobile text
messages [14], home [43] and community-based HIV
testing [44, 45] have also been recommended to meet
the HIV diagnosis target. Furthermore, encouraging
repeat HIV testing [46, 47], HIV testing services delivery
by lay workers [48], and self-testing [49] can tackle the
substantial gap in HIV diagnosis in low-income coun-
tries like Ethiopia. The mandatory HIV testing strategy
that has been implemented in China since 2005 for test-
ing at-risk groups such as drug users, inmates, and com-
mercial sex workers along with their clients was found
to be an effective strategy to heighten early HIV
diagnosis [7] that Ethiopia could consider. Interventions
such as lay counselor home visits [50], home visits by
peer supporters [51] and informational brochure
provision [52] were also important programs in linking
patients to ART clinics timely after HIV testing. In
Table 2 Clinical & non-clinical characteristics of HIV infected people enrolled in ART care in Southwest Ethiopia from 2003 to 2015
(Continued)
Variable Children (N = 399) Adult (N = 4900)
N (%) N (%)
Yes 5 (2.3) 29 (0.6)
Missing 180 (45.1) 1681 (34.3)
Baseline functional status Appropriate 170 (42.6) –
Delay or regression 229 (57.4) –
Baseline functional status Work or Ambulatory – 3064 (62.5)
Bedridden – 1437 (29.3)
Missing – 399 (8.1)
Timing to HIV care presentation Early 162 (40.6) 894 (18.2)
Late 215 (53.9) 1788 (36.5)
Missing 22 (5.5) 2218 (45.3)
Baseline CD4 count in cells/mm3 by HIV
care enrollment period (median (range))
enrolled in 2003–11 273 (0–2000) 119 (0–1641)
enrolled in 2012 and after 368 (3–2247) 178 (0–1638)
aOrthodox, Catholic, Protestant
Fig. 1 Trends in the percentage distribution of late presentation for
HIV care among HIV infected people on ART, Southwest
Ethiopia, 2004-2014
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addition, the application of rapid or point of care CD4
count technology has shown to enhance the number of
eligible patients for ART whereby the frequency of
appointments is reduced, and early ART initiation is
increased [53].
Compared to the early presenters, great majority of
late presenters had died in the current study, and this
is similar with findings from other studies conducted
elsewhere [54, 55]. It is plausible therefore to argue
that late presentation leads to a greater risk of: rapid
progression to advanced AIDS stage, compromised
immune response, poor treatment response, and
finally death [3]. Similarly, consistent with findings of
other studies [56, 57], the majority of adults who pre-
sented late for care had discontinued and developed
immunologic failure. This could be highly possible
since late presenters progress easily to advanced AIDS
stage, a stage characterized by marked CD4 reduction,
multiple comorbidities and poor overall functional
status [58, 59]. Subsequently, this leads to poor
immune recovery even after treatment initiation, and
increases the likelihood of ART toxicity that deters
patients to take the treatment regularly [60]. The
prevalence of LP among adults was higher than
children. This might largely be due to the ‘opt out’
screening programs for pregnant women and delivery
of HIV care (testing and treatment) to children born
to affected mothers timely [61].
Adult late presenters were more likely to be younger,
females, Tb/HIV co-infected, with no history of HIV
testing and enrolled to HIV care in 2011 and before.
Unlike other studies in Africa [62, 63], older adults were
less likely to delay for HIV care than their younger coun-
terparts. We found the finding surprising. HIV disease
progresses with time, and it would be expected, that
individuals diagnosed with HIV at a higher age would
also have advanced disease progression (lower CD4 cell
count) because they, on average, had a longer time span
between time of infection and time of diagnosis. How-
ever, the presence of high HIV related stigma among
young adults [64] hampers HIV testing and may be
linked to delays in seeking HIV care. In addition, it is
also possible that older adults assume a caring responsi-
bility for their family and might realise the need to
access HIV care service consistently increase their
longevity and to achieve the self-imposed caring respon-
sibility. Unlike in some others [56, 63], females were
more likely than males to delay for HIV care. This might
be because females have low understanding and compre-
hensive HIV care knowledge [3]. The high probability of
females for LP might also be explained by the fact that
62% of females in care did not have a previous history of
HIV testing. Females are also known to use traditional
healers more than males, which may lead to commen-
cing the HIV care late [3, 35].HIV related stigma is
higher among females than males [65]. It is also known
that the health seeking behaviours of females in urban
and rural southwest Ethiopia are lower compared to
males [66].
The association between Tb/HIV co-infection with
increased LP replicate findings from other studies [4]. It
has been stated that Tb is inextricably linked with HIV,
causes a synergistic combination of illness with HIV,
facilitates the progression of HIV disease to advanced
stage, and thereby deters patients from linking to care
timely [31]. Furthermore, focus has to be given for Tb/
HIV co-infection, as Tb remains the highest mortality
risk among HIV infected patients [13]. The absence of
previous history of HIV testing in association with LP
could be linked with poor awareness of the care [3], less
access to HIV testing and/or ART clinic [39], high HIV
related stigma [67], fear of diagnosis [68] and feeling of
wellbeing [69].HIV patients who were enrolled for HIV
care in 2012 and after were less likely to present late for
HIV care as compared to those enrolled in 2011 and
before. This may be attributed to: i) improving
Table 3 Outcomes of late presentation for HIV care among HIV infected children and adults enrolled in HIV care in southwest
Ethiopia, 2016
Age Variable Mortality Discontinuation Immunological status
Alive, n(%) Death, n(%) Retained, n(%) Discontinued, n(%) IS, n(%) IF, n(%)
Children EP 64 (44.8) 3 (42.9) 64 (44.8%) 21 (67.7) 40 (25.3) 1 (3.1)
LP 79 (55.2) 4 (57.1) 79 (55.2%) 10 (32.3) 118 (74.7) 31 (96.9)
Total 143 (100) 7 (100) 143 (100) 31 (100) 158 (100) 32 (100)
P-value (of X2) 0.921 0.020 0.005
Adults EP 459 (33.1) 65 (35.3) 459 (33.1) 184 (34.7) 682 (36.5) 99 (21.3)
LP 927 (66.9) 119 (64.7) 927 (66.9) 347 (65.3) 1187 (63.5) 365 (78.7)
Total 1386 (100) 184 (100) 1386 (100) 531 (100) 1869 (100) 464 (100)
P-value (of X2) 0.550 0.524 < 0.001
EP early presentation for HIV care, LP late presentation for HIV care presentation, IF immunologic failure, IS Immunologic success, X2 Chi-square
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Table 4 Logistic regression findings of factors linked with late presentation for HIV care in HIV infected people, JUTH, Southwest
Ethiopia, 2016
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0.4 (0.3–0.6)a 0.5 (0.4–0.7)a
50+ – – 59 (40.7) 86 (59.3) – 0.4
(0.3–0.7)a
0.4 (0.2–0.6)a 0.4 (0.3–0.6)a




609 (62.9) 1 1 1 1














Marital status Never married – – 151
(30.2)
349 (69.8) – – 1 1 1






509 (68.1) – – 0.9 (0.7–1.2) 0.9 (0.6–1.1) 0.9 (0.7–1.2)
Educational status No education – – 149
(32.5)
309 (67.5) – – 1
Primary – – 320
(34.8)





722 (69.8) – – 1.1 (0.9–1.4)
Religion Muslim 16 (37.2) 27 (62.8) 245
(33.1)
496 (66.9) 1 1 1








1.1 (0.9–1.3) 1.02 (0.9–1.2)








1 1 1 1 1




























– – 542 (32) 1150 (68) – – 1 1 1






Yes 162 (43) 215 (57) 529 (34.4) 1008 65.6) – – 1 1 1
No 0 0 365 (31.9) 780 (68.1) – – 1.1 (0.9–1.3) 1.2 (1.1–1.4)a 1.1
(1.00–1.3)a
HIV care enrollment period enrolled in 2003–11 128 (42.2) 175 (57.8) 698 (32.1) 1478 (67.9) 1 1 1 1




0.8 (0.7–0.9)a 0.7 (0.5–0.9)a
COR crude odds ratio, AOR adjusted odds ratio, CI confidence interval, Tb/HIV tuberculosis/HIV, ART antiretroviral therapy,astatistically significant at P-value = 0.05;
borthodox, protestant, catholic
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awareness to HIV care; ii) improving access and
availability to HIV care; and iii) reducing perceived HIV
related stigma.
The study has the following limitations. Firstly, data
were collected from JUTH, a referral hospital that also
receives referrals of patients with advanced stage. Hence,
these study participants are not necessarily representa-
tive of HIV patients who attend their follow up in health
centers or lower health care setups. Secondly, we did not
assess the annual proportions of LP across HIV testing
strategies (voluntarily counseling and testing, provider
initiated HIV testing and counseling (PITC), Outreach
or ‘opt out). Previous studies have shown that PITC was
not found more effective program for early HIV diagno-
sis than targeted HIV counseling [7]. Thirdly, the use of
conservative definitions for LP is not able to differentiate
whether the late presentation is before diagnosis,
between diagnosis and first entry to care, and between
first entry to care and ART initiation. A gold standard
definition for LP among general HIV positive population
and special groups such as HIV positive mothers and
Tb/HIV co-infected patients for low-income countries is
yet to be established. Fourthly, we found no statistically
significant predictor for LP among children, and this
could be due to small sample size. Finally, the presence
of incomplete data may bias the precision of estimates.
However, even with the aforementioned limitations,
the study sheds light and underpins the high prevalence
of LP. Furthermore, the research assessed outcomes and
risk factors for LP across ages, recommended effective
programs and benchmarking strategies to tackle LP, and
further achieve the ambitious UNAIDS targets.
Conclusions
In summary, three of five HIV infected people presented
late for HIV care, and the annual proportions of LP per-
sistently remained high across the 10 year period. The
majority of HIV infected children and adults who pre-
sented late for care had discontinued, transferred out
and developed immunologic failure. Late presenters
(adults) were more likely to be younger, females, Tb/
HIV co-infected, no history of HIV testing before diag-
nosis, and enrolled to HIV care before 2012. A large
sample size should be considered to assess factors influ-
encing for LP among children. Prioritizing the aforemen-
tioned risk factors, tremendous efforts are necessary to
curb LP and further achieve the UNAIDS goal. Some of
the strategies and programs that help to decline LP are
use of innovative technologies, home and community
based HIV testing, encouraging repeat and self-HIV test-
ing, mandatory HIV testing and effective linking strat-
egies to care after HIV diagnosis. HIV related stigma
should also contextually be tackled since it continues to
be a lingering issue among HIV infected people.
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